Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00506129 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00506129: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00506129 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00506129, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to see if receiving a transplant of blood stem cells (cells that can produce blood) or bone marrow from either a related donor (brother, sister or other relative) or an unrelated voluntary donor will help patients with advanced cutaneous T-cell lymphoma. The length of time that patients who receive the treatment remain free of disease will also be studied.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Thymoglobulin
- PROCEDURE Allogeneic Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2003-09 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00506129
The ClinicalTrials.gov registry entry for NCT00506129 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fludarabine is the first listed.
NCT00506129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00506129 about?
NCT00506129 is a clinical study titled "Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma". The goal of this clinical research study is to see if receiving a transplant of blood stem cells (cells that can produce blood) or bone marrow from either a related donor (brother, sister or other relative) or an unrelated voluntary donor will help patients with advanced cutaneous T-cell lymphoma. T...
What is the current status of trial NCT00506129?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2003-09. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00506129?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Thymoglobulin (DRUG), Allogeneic Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00506129?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.